Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Systematic review of occupational therapy-related interventions for people with multiple sclerosis: part 1. Activity and participation.
Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: Results from a longitudinal study.
Mode of action and clinical studies with fumarates in multiple sclerosis.
Methods for identifying subject-specific abnormalities in neuroimaging data.
Brain glycolipids suppress T helper cells and inhibit autoimmune demyelination.
Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects.
The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice.
Obturator neurolysis using 65% alcohol for adductor muscle spasticity.
Switching Therapies in Multiple Sclerosis.
Clinical impact of early brain atrophy in clinically isolated syndromes.
Fingolimod therapy for multiple sclerosis.
Aquaporin-4 antibody negative recurrent isolated optic neuritis: Clinical evidence for disease heterogeneity.
Understanding hope in patients with Multiple Sclerosis.
White matter disease: Early treatment of inflammatory demyelinating disease.
A pilot study of a telehealth intervention for persons with spinal cord dysfunction.
Benign neuromyelitis optica is rare in Japanese patients.
The +190 G/A (rs1799864) polymorphism in the C-C chemokine receptor 2 (CCR2) gene is associated with susceptibility to multiple sclerosis in HLA-DRB1*15:01-negative individuals.
Evaluation of the Multiple Sclerosis Walking Scale-12 (MSWS-12) in a Dutch sample: Application of item response theory.
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.
Deep grey matter MRI abnormalities and cognitive function in relapsing-remitting multiple sclerosis.
A Further TWEAK to Multiple Sclerosis Pathophysiology.
Massive peripheral nerve hypertrophy in a patient with chronic inflammatory demyelinating polyradiculoneuropathy.
JCV epidemiology in MS (JEMS)-Epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients-Portuguese data.
The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.
Variations in predicted risks in personal genome testing for common complex diseases.

Pages